Literature DB >> 23399647

Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.

Gaël Chételat1.   

Abstract

The amyloid cascade hypothesis, which posits that amyloid-β accumulation is the key event in Alzheimer disease neurodegeneration, has dominated the field for 20 years. Recent findings, however, show that neuronal-injury biomarkers are independent of amyloid-β, calling for reconsideration of the pathological cascade and assessment of alternative therapeutic strategies.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23399647      PMCID： PMC3935395          DOI： 10.1038/nrneurol.2013.21

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease.

Authors:  G Chételat; B Desgranges; B Landeau; F Mézenge; J B Poline; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Brain       Date:  2007-12-05       Impact factor: 13.501

3.  Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging.

Authors:  William J Jagust; Susan M Landau
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

4.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

Authors:  D S Knopman; C R Jack; H J Wiste; S D Weigand; P Vemuri; V Lowe; K Kantarci; J L Gunter; M L Senjem; R J Ivnik; R O Roberts; B F Boeve; R C Petersen
Journal:  Neurology       Date:  2012-05-02       Impact factor: 9.910

5.  An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.

Authors:  Clifford R Jack; David S Knopman; Stephen D Weigand; Heather J Wiste; Prashanthi Vemuri; Val Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Robert J Ivnik; Rosebud O Roberts; Walter A Rocca; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2012-04-09       Impact factor: 10.422

6.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

7.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

8.  Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.

Authors:  Renaud La Joie; Audrey Perrotin; Louisa Barré; Caroline Hommet; Florence Mézenge; Méziane Ibazizene; Vincent Camus; Ahmed Abbas; Brigitte Landeau; Denis Guilloteau; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

9.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Authors:  Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

10.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245
  10 in total
  79 in total

Review 1.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

Review 2.  The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

Authors:  Russell H Swerdlow; Jeffrey M Burns; Shaharyar M Khan
Journal:  Biochim Biophys Acta       Date:  2013-09-23

Review 3.  Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

Authors:  M Isabel G Lopez Sanchez; Peter van Wijngaarden; Ian A Trounce
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

4.  Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.

Authors:  Anna Caroli; Annapaola Prestia; Samantha Galluzzi; Clarissa Ferrari; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte Teunissen; Anders E Wall; Stephen F Carter; Michael Schöll; Il Han Choo; Timo Grimmer; Alberto Redolfi; Agneta Nordberg; Philip Scheltens; Alexander Drzezga; Giovanni B Frisoni
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

5.  Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine.

Authors:  Jan Booij; Javier Arbizu; Jacques Darcourt; Swen Hesse; Flavio Nobili; Pierre Payoux; Sabina Pappatà; Klaus Tatsch; Zuzana Walker; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

6.  Reply: The amyloid cascade is not the only pathway to AD.

Authors:  Gaël Chételat
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

7.  Can tauopathy shake the amyloid cascade hypothesis?

Authors:  Venugopalan Y Vishnu
Journal:  Nat Rev Neurol       Date:  2013-05-14       Impact factor: 42.937

Review 8.  Spreading of pathology in neurodegenerative diseases: a focus on human studies.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2015-01-15       Impact factor: 34.870

Review 9.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

10.  Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.

Authors:  Niklas Mattsson; Philip Insel; Rachel Nosheny; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Duygu Tosun; Michael Weiner
Journal:  Neurobiol Aging       Date:  2013-10-01       Impact factor: 4.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.